@bruixj Interesting, but not really surprisingπ«’. The primary endpoint is non-inferiority to sorafenib. That is an βeasyβ targetβ¦
09 Aug 22copy & paste+upvote-downvote@bruixj Interesting, but not really surprisingπ«’. The primary endpoint is non-inferiority π’to sorafenib. That is an βeasyβ targetβ¦
β@_lexiemichelee: @MariaCabayubi you know how slow I am Maria. But it looks really goodβhah I know this. But thank youuu
14 Jan 13copy & paste+upvote-downvoteβ@_lexiemichelee: @MariaCabayubi you know how slow I am Maria. But it looks really goodππππβhah I know this. But thank youuu βΊπππ